714 assets in Colorectal Cancer

Therapeutic assets addressing Colorectal Cancer, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Crizotinib Colorectal Cancer	Oslo University Hospital	P2	CCC (53)
Dalmitamig Colorectal Cancer	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	P2	CCC (53)
Danvatirsen Colorectal Cancer	M.D. Anderson Cancer Center	P2	CCC (53)
Darizmetinib Colorectal Cancer	Mayo Clinic	P2	CCC (53)
Defactinib Colorectal Cancer	M.D. Anderson Cancer Center	P2	CCC (53)
Denikitug Colorectal Cancer	Gilead Sciences	P2	CCC (53)
Dostarlimab Colorectal Cancer	Ibrahim Halil Sahin	P2	CCC (53)
Eflornithine Colorectal Cancer	Aminex Therapeutics, Inc.	P2	CCC (53)
Enzalutamide Colorectal Cancer	Exelixis	P3	CCC (53)
Genetically-Modified Oncolytic Type 5 Adenovirus Which Selectively Replicates In Tumor Cells Containing Dysfunctional P53 Gene (H101) Colorectal Cancer	Jun Huang	P2	CCC (53)
(±)-Gossypol Acetic Acid Colorectal Cancer	Guiying Wang	P2	CCC (53)
Hrs-4642 Colorectal Cancer	Fudan University	P2	CCC (53)
Hrs-7058 Colorectal Cancer	Fudan University	P2	CCC (53)
Human Adenovirus C Serotype 5 Colorectal Cancer	Thomas Jefferson University	P2	CCC (53)
Immunoglobulin G4 (227-Proline), Anti-(Human Programmed Cell Death Protein 1) (Human Monoclonal Psb103 .Gamma.4-Chain), Disulfide With Human Monoclonal Psb103 .Kappa.-Chain, Dimer Colorectal Cancer	Shanghai Changzheng Hospital	P2	CCC (53)
js015 Colorectal Cancer	Shanghai Junshi Bioscience Co., Ltd.	P2	CCC (53)
js207 Colorectal Cancer	Shanghai Junshi Bioscience Co., Ltd.	P2	CCC (53)
Leflunomide Colorectal Cancer	N.N. Petrov National Medical Research Center of Oncology	P2	CCC (53)
Monalizumab Colorectal Cancer	Assistance Publique - Hôpitaux de Paris	P2	CCC (53)
ngm120 Colorectal Cancer	NGM Biopharmaceuticals, Inc	P2	CCC (53)
Nilotinib Colorectal Cancer	National Cancer Institute (NCI)	P2	CCC (53)
Niraparib Colorectal Cancer	Ibrahim Halil Sahin	P2	CCC (53)
Normal Human Serum Albumin Colorectal Cancer	Joachim Zdolsek	P4	CCC (53)
Olanzapine Colorectal Cancer	OHSU Knight Cancer Institute	P2	CCC (53)
Ongericimab Colorectal Cancer	Shanghai Pudong Hospital	P2	CCC (53)
pds01adc Colorectal Cancer	National Cancer Institute (NCI)	P2	CCC (53)
Pimurutamab Colorectal Cancer	Shanghai Henlius Biotech	P2	CCC (53)
pm8002 Colorectal Cancer	Biotheus Inc.	P2	CCC (53)
Ponsegromab Colorectal Cancer	Pfizer	P2	CCC (53)
rp2 Colorectal Cancer	Replimune, Inc.	P2	CCC (53)
rp3 Colorectal Cancer	Replimune, Inc.	P2	CCC (53)
sg001 Colorectal Cancer	Shanghai JMT-Bio Inc.	P2	CCC (53)
Sgm-101 Colorectal Cancer	Leiden University Medical Center	P2	CCC (53)
SR-8541A Colorectal Cancer	Stingray Therapeutics	P2	CCC (53)
Ssgj-706 Colorectal Cancer	Shenyang Sunshine Pharmaceutical Co., LTD.	P2	CCC (53)
Thalidomide Colorectal Cancer	Xinqiao Hospital of Chongqing	P2	CCC (53)
tl938 capsules Colorectal Cancer	Suzhou Teligene Ltd.	P2	CCC (53)
Tunlametinib Colorectal Cancer	Chinese PLA General Hospital	P2	CCC (53)
Vancomycin Colorectal Cancer	M.D. Anderson Cancer Center	P2	CCC (53)
1.0% ip-001 for Colorectal Cancer	Immunophotonics, Inc.	P2/3	CCC (52)
Bafisontamab Colorectal Cancer	Shanghai EpimAb Biotherapeutics Co., Ltd.	P2	CCC (52)
Bevacizumab-Awwb Colorectal Cancer	Amgen	P3	CCC (52)
bp102 Colorectal Cancer	West China Hospital	P2/3	CCC (52)
Canagliflozin Colorectal Cancer	West China Hospital	P1/2	CCC (52)
Duloxetine Colorectal Cancer	Alliance for Clinical Trials in Oncology	P2/3	CCC (52)
Hydroxychloroquine Colorectal Cancer	Sergey Orlov, MD	P2	CCC (52)
ip-001 Colorectal Cancer	Immunophotonics, Inc.	P2/3	CCC (52)
Jab 3312 Colorectal Cancer	Allist Pharmaceuticals, Inc.	P1/2	CCC (52)
Methotrexate Colorectal Cancer	Sergey Orlov, MD	P2	CCC (52)
Nitazoxanide Colorectal Cancer	Tanta University	P3	CCC (52)

Showing 151 to 200 of 714 assets

PreviousPage 4 of 15Next